Using vagus nerve stimulation to restore inflammatory control

A clinician's guide to neuromodulation

Over the past two decades, a growing body of research has reframed chronic inflammation not as an isolated immune malfunction, but as a failure of neural regulation. Landmark work on the inflammatory reflex demonstrated that immune activity is continuously controlled by the nervous system, mediated primarily through the vagus nerve. When this regulatory circuit is intact, inflammatory responses are proportional, time-limited, and self-resolving. When it fails, inflammation persists and spreads systemically, contributing to chronic disease across organ systems.

In Part I of this series, we outlined the physiology of the inflammatory reflex and its role as a closed-loop neuroimmune control system. In this second and final paper, we move from framework to intervention. Here, we examine how vagus nerve stimulation (VNS) and targeted lifestyle-based neuromodulation can be combined to restore regulatory control, reduce the inflammatory burden, support resolution, and address chronic disease at its upstream control point.

As vagus nerve stimulation devices have become widely available through consumer marketplaces, the concept of a ‘vagal reset’ has been increasingly promoted in wellness and social media spaces. It is crucial to distinguish informal wellness practices from clinical neuromodulation, which carries physiological effects, contraindications, and dose-dependent risks that warrant medical oversight.

When VNS is relevant

This regulatory model is most useful when symptoms suggest a breakdown in system-level coordination, rather than dysfunction isolated to a single organ. Clinically, this often presents with symptoms that span multiple domains, including fatigue, pain, cognitive impairment, gastrointestinal disturbance, sleep disruption, and orthostatic symptoms that fluctuate with stress, illness, exertion, or circadian disruption, rather than following a single anatomical or biochemical pathway.

These patients frequently demonstrate poor recovery after otherwise minor stressors or infections and show signs of chronic or relapsing inflammation that cannot be fully explained by one dominant disease process. In such cases, impaired autonomic and neuroimmune regulation offers a unifying framework for understanding symptom persistence and fragility.

Clinically, this regulatory approach is most effective when applied sequentially: first identifying patterns of impaired regulation, then reducing autonomic load, and finally layering neuromodulatory and conditioning inputs to restore physiological flexibility. This sequencing matters, as premature stimulation in the setting of unresolved autonomic stress often produces inconsistent or blunted responses.

How neuromodulation changes the inflammatory model

Under physiological conditions, inflammatory mediators released in peripheral tissues activate sensory (afferent) fibers of the vagus nerve. These afferent fibers do not merely transmit information passively; they function as a real-time surveillance system, continuously reporting immune activity to the brainstem.

Afferent vagal fibers project primarily to the nucleus tractus solitarius (NTS), a brainstem structure that serves as a central integration hub for visceral information. The NTS does not process immune signals in isolation. Instead, it integrates immune input with cardiovascular status, respiratory rhythm, metabolic state, circadian timing, and stress-related signals arriving from higher brain centers.

Once processed centrally, coordinated efferent vagal output restrains excessive immune activation, particularly through macrophage signaling. This does not result in immune suppression, but proportional inhibition, allowing inflammation to resolve rather than propagate.

The inflammatory reflex operates on a timescale of seconds, distinguishing neural regulation from endocrine or pharmacologic approaches and helping explain why cytokine blockade alone often fails to restore balance.

Measuring vagal regulatory failure

Before attempting to restore vagal regulation, clinicians must recognize when it is impaired. Heart rate variability (HRV) provides a practical, non-invasive window into this system.

HRV reflects variability between successive heartbeats, driven primarily by parasympathetic (vagal) modulation of cardiac rhythm. While measured at the heart, this modulation reflects broader vagal output affecting multiple systems, including immune regulation. Persistently reduced HRV suggests diminished inhibitory capacity, increasing vulnerability to prolonged inflammation, exaggerated stress responses, and impaired recovery.

Low HRV is commonly observed in conditions marked by fatigue, pain sensitization, orthostatic intolerance, and cognitive dysfunction, including fibromyalgia, Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), Postural Orthostatic Tachycardia Syndrome (POTS), inflammatory bowel disease, and long COVID. However, HRV is sensitive to sleep, circadian rhythm, infection, medications, alcohol, and psychological stress.

Importantly, HRV reflects vagal modulation at the level of the heart, but it is not a comprehensive measure of vagal function. Vagal dysregulation may also be evident through orthostatic intolerance, stress-sensitive gastrointestinal motility disturbances, impaired inflammatory resolution, or multisystem symptom clustering—even when resting HRV appears within normal ranges.

As with any clinical intervention, VNS should be paired with appropriate monitoring to assess response and guide continuation. Improvements are best evaluated through functional measures such as HRV trends, orthostatic tolerance, sleep quality, recovery time, and symptom patterns, rather than subjective sensation alone.

Interpreting heart rate variability in a clinical context

Taken together, these observations underscore the need to interpret HRV in context. HRV should be understood as an indicator of regulatory capacity rather than a direct measure of health, fitness, or disease. There is no universal HRV value that defines health; baseline values vary widely with age, sex, genetics, fitness level, medications, and individual autonomic architecture.

For orientation only, commonly reported Root Mean Square of Successive Differences (RMSSD, referring to a heart rate variability metric reflecting short-term, parasympathetic activity) values below ~20 ms are often seen in states of autonomic impairment or acute physiological load; 20–40 ms is typical under sustained stress or sedentary conditions; 40–70 ms is typical of individuals with adequate autonomic flexibility; and higher values are frequently observed in endurance-trained populations.

These ranges are not diagnostic, and higher is not inherently better. Health is defined by adaptability and recovery.

Clinically useful HRV assessment depends on consistency rather than precision. RMSSD is the most informative metric for vagal modulation and should be interpreted longitudinally under standardized conditions. Persistent suppression or loss of recovery following rest is more instructive than day-to-day fluctuation.

Invasive vs non-invasive stimulation

Implanted cervical VNS stimulates both afferent and efferent fibers directly and has demonstrated durable anti-inflammatory effects in refractory rheumatoid arthritis and Crohn’s disease. These outcomes suggest that repeated activation of vagal circuits can recalibrate immune set-points over time.

Non-invasive transcutaneous approaches primarily stimulate afferent fibers. This is not a limitation: afferent signaling is the gateway to central integration, which then coordinates downstream regulation across systems. However, effectiveness depends on sufficient intensity, appropriate targeting, and cumulative exposure.

Non-response is frequently attributable to subthreshold stimulation rather than to failure of the underlying model; studies demonstrating benefit typically employ frequencies in the 20–25 Hz range, with adequate pulse width and cumulative dosing.

While non-invasive VNS devices are readily accessible and relatively simple to use (a wearable clip on or near the ear or a handheld device pressed against the side of the neck), their quality, output, and targeting vary widely.

VNS is not for all individuals, and caution must be taken for individuals with implanted electronic devices, cardiac abnormalities, specific medication profiles, and those who are pregnant.

A qualified medical or clinical practitioner should guide the use of these devices to ensure appropriate selection, parameter settings, and patient suitability, as subtherapeutic or poorly targeted stimulation may lead to false assumptions about efficacy.

Moving beyond cytokines to support inflammatory resolution

Early VNS studies focused on reductions in TNF-α and IL-6 as markers of success. While important, cytokines represent only one phase of inflammation. Recovery requires resolution: the active termination of immune responses and initiation of tissue repair.

Preclinical research suggests that vagus nerve stimulation influences inflammation not only by reducing cytokine output, but by actively supporting the body’s ability to shut an inflammatory response down once it has served its purpose. One mechanism by which this occurs is accelerated clearance of neutrophils, the short-lived immune cells that are the first to arrive at sites of tissue injury or infection.

When neutrophils remain in tissue longer than necessary, they perpetuate local damage and ongoing immune activation. VNS appears to shorten this phase by promoting the timely removal.

VNS also influences lipid mediator pathways that generate specialized pro-resolving mediators (SPMs). These molecules act as biological stop signals, instructing immune cells to disengage, regulate residual inflammation, and restore tissue integrity. Clinically, impaired resolution helps explain prolonged flares, delayed recovery, and cumulative symptom burden even when inflammatory markers appear modest.

VNS alone is not sufficient

Neural circuits do not operate in isolation. Their responsiveness depends on neurotransmitter availability, membrane composition, afferent signal quality, and central integration. For this reason, lifestyle inputs are best understood as external neuromodulators rather than wellness strategies.

Slow, controlled breathing alters intrathoracic pressure, directly stimulating vagal afferents linked to baroreceptor and cardiopulmonary feedback. These signals converse in the NTS, reinforcing parasympathetic dominance and improving autonomic flexibility. While breathing practices do not directly suppress cytokines, they improve the signal environment within which immune regulation occurs.

Acute cold exposure activates reflexive parasympathetic responses, including the diving reflex, which increases vagal output and suppresses sympathetic tone. Although clinical trials directly linking cold exposure to inflammatory reflex engagement are limited, the underlying neural pathways overlap substantially with those targeted by VNS.

Vagal tone follows circadian rhythms. Sleep disruption fragments autonomic regulation, sustaining sympathetic dominance and impairing immune restraint. Restoring consistent sleep timing improves the nervous system’s ability to interpret and respond appropriately to immune signals.

Nutrition as a determinant of regulatory capacity

Omega-3 fatty acids serve as substrates for the production of specialized pro-resolving mediators (SPMs). This class of lipid-derived signaling molecules actively coordinates the resolution phase of inflammation.

Dietary patterns that support inflammatory resolution, such as those rich in omega-3 fatty acids, polyphenols, and fermentable fibers, may enhance downstream responsiveness once regulatory signaling is restored, without acting as primary drivers themselves. Excess alcohol intake, irregular meal timing, and chronic stimulant use can increase autonomic noise and blunt neuromodulatory effects, particularly in patients with already reduced regulatory reserve.

In clinical practice, dysbiosis, increased intestinal permeability, or persistent low-grade gut inflammation can introduce excessive afferent ‘noise,’ blurring signal clarity to the brainstem, and reducing responsiveness to vagus nerve stimulation or other regulatory interventions.

Addressing gut-related contributors such as meal timing, fermentable substrate load, and inflammatory burden does not substitute for neuromodulation. Still, it can materially improve the fidelity of afferent signaling and the consistency of downstream regulation.

Acetylcholine is the effector neurotransmitter of vagal immune restraint. Adequate choline intake ensures substrate availability but does not override neural control. Practically, this means nutrition supports capacity; regulation still depends on circuit engagement.

Clinical synthesis

In practice, this framework is most useful when applied sequentially: first, identifying patterns of impaired regulation; then, reducing autonomic load; and finally, layering neuromodulatory and conditioning inputs to restore flexibility. VNS and lifestyle-based neuromodulation are complementary approaches alongside standard care. They address the regulatory layer that determines whether inflammation resolves or persists.

The shift from suppression to regulation does not eliminate the need for disease-specific treatment. It restores the system that governs proportion, timing, and recovery. For practitioners managing chronic, relapsing, or multisystem inflammatory conditions, this regulatory lens offers a coherent approach to upstream intervention, where control, rather than containment, becomes possible.

For these reasons, vagus nerve stimulation should be used as a clinical tool, applied deliberately, monitored over time, and integrated into broader care, rather than as a standalone or unsupervised self-experiment.

In conclusion

For many practitioners, chronic inflammation presents not as a single disease to be treated, but as a pattern of fragility: patients who relapse easily, recover slowly, and accumulate symptoms across systems despite appropriate disease-specific care. What unites these presentations is impaired physiological regulation.

The framework outlined here provides a means of identifying and addressing coordination failures. Vagal regulation does not replace immunology, rheumatology, or pharmacology; it determines how effectively those systems are integrated, restrained, and resolved. When inhibitory control is intact, inflammatory responses remain proportional and time-limited.

When compromised, even modest stressors such as illness, exertion, and sleep disruption can trigger prolonged or cascading effects.

Clinically, this shifts the task from suppressing signals to restoring control. It encourages practitioners to look beyond isolated biomarkers or organ systems and instead assess adaptability, recovery, and coherence across domains. Heart rate variability, orthostatic responses, gastrointestinal function, sleep patterns, and symptom fluctuation are not merely ancillary observations but clues to regulatory capacity.

Neuromodulation, whether delivered through vagus nerve stimulation or conditioned through behavioral and lifestyle inputs, is most effective when applied within a physiological context that supports signal clarity and responsiveness. Reducing autonomic load, stabilizing circadian rhythms, and supporting resolution biology do not compete with stimulation; they determine whether it works.

In moving from suppression to regulation, the goal is not to do more but to enable the body to complete what it has already begun: an appropriate response, followed by resolution.

Disclaimer

This article is written for clinicians and scientific readers. It provides evidence-based information on vagus nerve stimulation and related concepts for educational purposes only. This does not constitute medical advice, diagnosis, treatment recommendations, or a substitute for professional healthcare guidance. Consult qualified healthcare providers for individual patient care purposes. No doctor-patient relationship was established by reading this content.

References

Austelle, C. W., O’Leary, G. H., Thompson, S., & Badran, B. W. (2024). Vagus nerve stimulation (VNS): Recent advances and future directions. Clinical Autonomic Research, 34, 529–547. https://doi.org/10.1007/s10286-024-01065-w

Badran, B. W., Yu, A. B., Adair, D., Mappin, G., DeVries, W. H., Jenkins, D. D., George, M. S., & Bikson, M. (2019). Laboratory administration of transcutaneous auricular vagus nerve stimulation (taVNS): Technique, targeting, and considerations. Journal of Visualized Experiments, (143), Article e58984. https://doi.org/10.3791/58984

Besson, C., Baggish, A. L., Monteventi, P., Schmitt, L., Stucky, F., Gremeaux, V., & Noirez, P. (2025). Assessing the clinical reliability of short-term heart rate variability: Insights from controlled dual-environment and dual-position measurements. Scientific Reports, 15(1), Article 5611. https://doi.org/10.1038/s41598-025-89892-3

Chen, Z., & Liu, K. (2025). Mechanisms and applications of vagus nerve stimulation. Current Issues in Molecular Biology, 47, Article 122. https://doi.org/10.3390/cimb47020122

Drewes, A. M., Brock, C., Rasmussen, S. E., Møller, H. J., Brock, B., Deleuran, B. W., & Farmer, A. D. (2021). Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: Results of a pilot study. Scandinavian Journal of Rheumatology, 50(1), 20–27. https://doi.org/10.1080/03009742.2020.1764617

Falvey, A. (2022). Vagus nerve stimulation and inflammation: Expanding the scope beyond cytokines. Bioelectronic Medicine, 8(1), Article 19. https://doi.org/10.1186/s42234-022-00100-3

Johnson, R. L., & Wilson, C. G. (2018). A review of vagus nerve stimulation as a therapeutic intervention. Journal of Inflammation Research, 11, 203–213. https://doi.org/10.2147/JIR.S163248

Kim, A. Y., Marduy, A., de Melo, P. S., et al. (2022). Safety of transcutaneous auricular vagus nerve stimulation (taVNS): A systematic review and meta-analysis. Scientific Reports, 12, Article 22055. https://doi.org/10.1038/s41598-022-25864-1

Lange, G., Janal, M. N., Maniker, A., Fitzgibbons, J., Fobler, M., Cook, D., & Natelson, B. H. (2011). Safety and efficacy of vagus nerve stimulation in fibromyalgia: A phase I/II proof-of-concept trial. Pain Medicine, 12(9), 1406–1413. https://doi.org/10.1111/j.1526-4637.2011.01203.x

Ma, L., Wang, H.-B., & Hashimoto, K. (2025). The vagus nerve: An old but new player in brain–body communication. Brain, Behavior, and Immunity, 124, 28–39. https://doi.org/10.1016/j.bbi.2024.11.023

Matsuoka, M., Yamaguchi, T., & Fujiwara, T. (2025). Transcutaneous auricular vagus nerve stimulation in healthy individuals, stroke, and Parkinson’s disease: A narrative review of safety, parameters, and efficacy. Frontiers in Physiology, 16, Article 1693907. https://doi.org/10.3389/fphys.2025.1693907

Tesser, J. R. P., Crowley, A. R., Box, E. J., et al. (2025). Vagus nerve–mediated neuroimmune modulation for rheumatoid arthritis: A pivotal randomized controlled trial. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-025-04114-7

Veldman, F., Hawinkels, K., & Keszthelyi, D. (2025). Efficacy of vagus nerve stimulation in gastrointestinal disorders: A systematic review. Gastroenterology Report, 13, Article goaf009. https://doi.org/10.1093/gastro/goaf009

Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, Article 1393371. https://doi.org/10.3389/fneur.2024.1393371